Overview

A Study to Investigate Safety and Pharmacokinetics of Intravenous Cefiderocol/Xeruborbactam in Participants With Renal Impairment

Status:
RECRUITING

Trial end date:
2026-12-23

Target enrollment:

Participant gender:

Summary

A Phase 1, Open-label, Single-dose Study to Determine the Safety and Pharmacokinetics of Intravenous Cefiderocol/Xeruborbactam (S-649228) in Participants with Renal Impairment

Phase:

PHASE1

Details

Lead Sponsor:

Qpex Biopharma, Inc.

Collaborators:

Biomedical Advanced Research and Development Authority
Shionogi Inc.

Treatments:

Cefiderocol
QPX7728